Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.48 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30042412 | 1.00 | MEN1 (0.49) | MEN1KMT2AATMTBK1VEGFA | |
| SCHEMBL209280 | 0.87 | TBK1 (0.55) | MEN1KMT2AATMTBK1VEGFA | |
| SCHEMBL30520640 | 0.86 | MEN1 (0.50) | MEN1KMT2AATMTBK1VEGFA | |
| SCHEMBL114519 | 0.85 | VEGFA (0.50) | MEN1KMT2AATMTBK1VEGFA | |
| SCHEMBL1997213 | 0.85 | MEN1 (0.49) | MEN1KMT2AATMTBK1VEGFA | |
| SCHEMBL12557699 | 0.85 | KMT2A (0.69) | MEN1KMT2AATMVEGFAEGLN1 | |
| SCHEMBL30584532 | 0.85 | MEN1 (0.49) | MEN1KMT2AATMTBK1VEGFA | |
| SCHEMBL31298334 | 0.84 | MEN1 (0.51) | MEN1KMT2AATMVEGFAEGLN1 | |
| SCHEMBL28653662 | 0.84 | MEN1 (0.48) | MEN1KMT2AATMTBK1VEGFA | |
| SCHEMBL21551092 | 0.84 | TBK1 (0.48) | MEN1KMT2AATMTBK1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-115028637-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-12-26 | — | — | US | disclosed |
| EP-3746072-B1 | 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | FOCHON BIOSCIENCES, LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
| EP-3369734-A1 | KINASE INHIBITOR, AND PREPARING METHOD AND PHARMACEUTICAL USE THEREOF | Gan & Lee Pharmaceuticals (CN) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017071516-A1 | KINASE INHIBITOR, AND PREPARING METHOD AND PHARMACEUTICAL USE THEREOF | 甘李药业股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130096136-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20130096136-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20130090327-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-11 | — | — | US | disclosed |
| US-20130090327-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-11 | — | — | US | disclosed |
| EP-2229377-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | MEN1 3154/4885KMT2A 1533/4885ATM 1716/4885 |
| US-20130096136-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | MEN1 2433/4885KMT2A 3825/4885ATM 1098/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | MEN1 2198/4885KMT2A 2161/4885ATM 3135/4885 |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | MEN1 3154/4885KMT2A 1533/4885ATM 1716/4885 |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | CDK4, CDK6, CDK2 | MEN1 2207/4885KMT2A 1384/4885ATM 275/4885 |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | MEN1 3154/4885KMT2A 1533/4885ATM 1716/4885 |
| US-20130090327-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | MEN1 2433/4885KMT2A 3825/4885ATM 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.